



SUVEN PHARMACEUTICALS LIMITED
4TH ANNUAL REPORT 2021-22



EMBRACING
OPPORTUNITIES
EXPLORING
POSSIBILITIES

	005	Embracing Opportunities
Exploring Possibilities	006	
	008	About Suven Pharmaceuticals
Key Performance Indicators	010	
	012	From the MD's Desk
A review of the Company's Performance	014	
	017	Management Discussion & Analysis
Sustainability & Social Responsibility	027	
	032	Board's Report
Report on Corporate Governance	052	
	070	Standalone Financial Statements
Consolidated Financial Statements	134	
	198	Notice



OPPORTUNITIES.....

.....NEVER GO

ABEGGING.....



EITHER YOU
TAKE IT, OR...



SOMEBODY ELSE WILL...

In today's fast-changing world, everything is and will change at an unprecedented pace.

Business relations. Business models. Business strategies.

Enterprises will need to mix things up to sustain business growth in the face of change.

Opportunities and possibilities will appear on the horizon.

Either with a bang or with a whisper...

Entrepreneurs need to be alive and agile to envision and enact them.

At Suven Pharma, while we continue to embrace opportunities that strengthen our existing edifice, we remain agile in exploring new possibilities that fortify our relevance in our enduring relationships.

These challenging moves, we are confident, will take us to

greater heights...





EMBRACING OPPORTUNITIES

DEEP AND WIDE CHEMISTRY SKILLS AND THEIR APPLICATION TO THE CUSTOMERS' REQUIREMENT IS OUR COMPETITIVE EDGE.

Armed with intellectual capital and capability matrix, we realise that we can partner with any global player anywhere across the pharma value chain. Hence, we moved from working on intermediates to developing formulation.

Our initial success with Mailthaion, which we developed and **partnered with Taro** spurred us on to establish a more meaningful presence in this space.

We took up the opportunity...

We have filed 17 ANDAs (up to March 31, 2022) of which we have got approval for 9 products and launched 8 products. In the last 3 years, our revenue has moved up steadily from ₹6.50 crores to ₹45.69 crores.

Along the way, interesting opportunities came up in the formulation ecosystem...

We clasped onto one of them, namely Rising Pharma which opened the doors to the US formulation distribution space. The value-accretion from this investment led to another exciting prospect in the form of Casper Pharma.


We took the plunge...

Casper Pharma came with a new manufacturing facility. Casper has agreement with Rising Pharma for next 7 years with 2 ANDAs filed and ready for US-FDA inspection anytime soon. With the addition of Casper Pharma, our portfolio of offering under formulations segment will improve in the next 3 to 5 years.

There is more on the anvil!

At Suven Pharma, we are embracing new opportunities that fit into our capability matrix and add wings to our growth aspirations.





EXPLORING POSSIBILITIES

IN OUR KIND OF BUSINESS RELATIONS ARE EVERYTHING. UNDERSTANDING THIS REALITY, WE HAVE WORKED PATIENTLY, DAY AFTER DAY, PROJECT AFTER PROJECT TO BUILD BONDS WITH GLOBAL INNOVATORS.



Demonstrating our service capability.
Living up to our commitments. Going
beyond commitment.

We deliver for more than 25 years...

We have worked with large
innovators, we have partnered with
start-up innovators in their journey.
And in doing so, we have transformed
our position with leading innovators
of today from being outside vendors
to inside business partners.

*This is our most prized intangible
asset which has been appreciated
in every single year of our business
journey...*

With this, we became preferred
vendor to four global players which
will enhance the new business
opportunities and expansion of our
offerings into forward integration of
the product development.

At Suven Pharma, we are exploring new possibilities
that will continue to enrich our business relations with
global innovators.



THIS IS **SUVEN PHARMA**

OUR BUSINESS

Suven Pharma is an integrated CDMO company with strong capabilities from process research & development to late-stage clinical and commercial manufacturing.

OUR CUSTOMERS

Suven Pharma partners leading Global Life Science and Fine Chemical majors in their innovation journey.

OUR SERVICES

Suven Pharma's services include Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations.

OUR NICHE

Suven has established its core competency in cyanation and heterocyclic chemistry, including pyrimidines, quinolones, thiazoles, and imidazoles, in addition to demonstrating our proficiency in Carbohydrate and Chiral chemistry including tetrahydrofurans, amino acids and sulfoxides and dabbled into each and every chemistry except fluorination and phosgenation from gram to multi-ton scale.

